BAL PHARMA LTD. - 524824 - Announcement under Regulation 30 (LODR)-Newspaper Publication
In compliance with Regulation 47 of SEBI(LODR) Regulations, we are submitting the newspaper advertisements of the abridged Audited standalone and consolidated financial results of the company for the quarter and year ended 31.03.2024 announced by the Company on 28.05.2024 and published in Financial Express ( English) and Snajayvani ( Kannada ) on 29.05.2024. BAL PHARMA LTD. - 524824 - Corporate Action-Board approves Dividend
Board of Directors of the Company at their meeting held on 28.05.2024 has recommended payment of Dividend of Re.1.20 paise per equity share of Rs.10 each i.e 12%, which is subject to the approval of the shareholders of the Company at the ensuing Annual General Meeting . BAL PHARMA LTD. - 524824 - Audited Financial Results 31.03.2024
Audited stand alone & Consolidated financial results for the quarter and financial year ended 31.03.2024 to gather with declaration of unmodified opinion and audit reports issued by statutory auditors. BAL PHARMA LTD. - 524824 - Board Meeting Outcome for Outcome Of The Board Meeting
Board of Directors of the Company has met today and inter alia transacted the following business, 1.Approved the audited financial results ( Stand alone & Consolidated ) for the quarter and financial year ended 31.03.2024. Copies of the approved financial results along with Declaration of Unmodified opinion and Audit reports issued by the statutory auditors are enclosed for submitting to the exchanges. 2. Recommended a Dividend of Rs.1.20 per equity share of Rs.10 each i.e 12% which is subject to the approval of shareholders at the ensuing AGM. 2. Reappointed Mr.M.R Krishna Murthy, Cost Accountant as Cost Auditor , M/s Murugesh & Co, Chartered Accountants as Internal auditors and Mr.Parameshwar Bhat, PCS as Secretarial Auditors of the Company for the F.Y 2024-25. BAL PHARMA LTD. - 524824 - Compliances-Reg.24(A)-Annual Secretarial Compliance
We are submitting the Annual Secretarial Compliance report duly certificated by the practicing Company Secretary for the financial year ended 31.03.2024. BAL PHARMA LTD. - 524824 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Intimation reg loss of Share Certificate BAL PHARMA LTD. - 524824 - Corporate Action-Board to consider Dividend
Please refer to our intimation regarding Board Meeting dated 30.04.2024. BAL PHARMA LTD. - 524824 - Board Meeting Intimation for Notice For The Board Meeting
BAL PHARMA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 28/05/2024 ,inter alia, to consider and approve 1.Audited Standalone and Consolidated financial results for the quarter and financial year ended 31.03.2024. 2.Audited standalone and consolidated accounts of the Company together with Directors and Auditors reports. 3. Recommendation of Dividend, if any, for the financial year ended 31.03.2024. 4.Appoinment of Internal Auditors, Cost Auditors and Secretarial Auditors for f.y ended 31.03.2024. BAL PHARMA LTD. - 524824 - Disclosure Of Statement Of Deviation/Veriation
Disclosure of Deviation / variation in utilization of issue proceeds from the objects stated in the explanatory statement to the notice of the general meeting for the quarter ended 31.03.2024 is not applicable for our Company i.e Bal Pharma Limited , as the preferential issue proceeds has been fully utilized. BAL PHARMA LTD. - 524824 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
We are submitting to the exchange intimation received from our R&T agent i.e Link Intime India Private Ltd, Mumbai regarding loss of share certificate by one of our shareholder.